Cas:1211518-50-1 3-Bromo-4-methyl-5-(trifluoromethyl)pyridine manufacturer & supplier

We serve Chemical Name:3-Bromo-4-methyl-5-(trifluoromethyl)pyridine CAS:1211518-50-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-Bromo-4-methyl-5-(trifluoromethyl)pyridine

Chemical Name:3-Bromo-4-methyl-5-(trifluoromethyl)pyridine
CAS.NO:1211518-50-1
Synonyms:3-bromo-4-methyl-5-trifluoromethyl-pyridine
Molecular Formula:C7H5BrF3N
Molecular Weight:240.02100
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:12.89000
Exact Mass:238.95600
LogP:3.17130

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-bromo-4-methyl-5-trifluoromethyl-pyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-bromo-4-methyl-5-trifluoromethyl-pyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-bromo-4-methyl-5-trifluoromethyl-pyridine Use and application,3-bromo-4-methyl-5-trifluoromethyl-pyridine technical grade,usp/ep/jp grade.


Related News: The vaccine also proved safe during the two-year trial, in which eleven doses were administered to randomly chosen patients with mild dementia. People who received the vaccine, known as AADvac1, experienced about the same numbers of side effects and adverse events as those who were given a placebo. 3-Bromo-4-methyl-5-(trifluoromethyl)pyridine manufacturer At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth. 3-Bromo-4-methyl-5-(trifluoromethyl)pyridine supplier At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth. 3-Bromo-4-methyl-5-(trifluoromethyl)pyridine vendor Health officials said it remained unclear where he had developed the disease. 3-Bromo-4-methyl-5-(trifluoromethyl)pyridine factory Health officials said it remained unclear where he had developed the disease.